Pfizer (NYSE:PFE – Get Free Report) posted its quarterly earnings data on Tuesday. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.09, FiscalAI reports. The business had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. Pfizer’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.78 EPS. Pfizer updated its FY 2026 guidance to 2.800-3.000 EPS.
Pfizer Stock Performance
Pfizer stock traded up $0.18 during trading hours on Tuesday, hitting $25.21. The stock had a trading volume of 13,371,496 shares, compared to its average volume of 42,054,219. The company has a 50-day moving average of $25.03 and a two-hundred day moving average of $26.16. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. The company has a market cap of $143.67 billion, a PE ratio of 19.18 and a beta of 0.34. Pfizer has a fifty-two week low of $23.58 and a fifty-two week high of $28.75.
Pfizer Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.8%. The ex-dividend date is Friday, July 24th. Pfizer’s payout ratio is currently 131.30%.
Analyst Ratings Changes
View Our Latest Stock Analysis on PFE
Trending Headlines about Pfizer
Here are the key news stories impacting Pfizer this week:
- Positive Sentiment: Pfizer posted adjusted earnings per share of $0.77, above the $0.68 consensus estimate, while revenue rose 2.6% year over year to $15.03 billion versus expectations of $14.40 billion. Pfizer second-quarter press release
- Positive Sentiment: Growth in non-COVID products, particularly the blood thinner Eliquis and oncology medicines, drove the quarterly beat and helped offset weakening COVID-19 product demand. Reuters Eliquis earnings article
- Positive Sentiment: Pfizer raised its 2026 revenue outlook to $60.5 billion-$62.5 billion from $59.5 billion-$62.5 billion, increasing the midpoint by $500 million. Management reaffirmed adjusted EPS guidance of $2.80-$3.00 despite an estimated $0.10 impact from its Innovent Biologics transaction. CNBC Pfizer earnings article
- Neutral Sentiment: The results reinforce Pfizer’s strategy of replacing pandemic-related revenue with oncology and other newer products, but investors will likely look for evidence that these businesses can sustain growth as COVID sales continue to shrink. Pfizer second-quarter results announcement
- Negative Sentiment: Pfizer swung to a second-quarter reported loss despite higher revenue. The modest guidance improvement may have fallen short of investor hopes following the earnings beat, contributing to weakness in the shares. Wall Street Journal Pfizer loss article
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the company. State Street Corp boosted its stake in Pfizer by 0.9% during the third quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company’s stock worth $7,620,747,000 after buying an additional 2,786,098 shares in the last quarter. Morgan Stanley lifted its holdings in shares of Pfizer by 19.2% during the 4th quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock worth $2,218,929,000 after acquiring an additional 14,342,946 shares during the period. Northern Trust Corp boosted its position in shares of Pfizer by 1.4% during the 3rd quarter. Northern Trust Corp now owns 64,019,807 shares of the biopharmaceutical company’s stock valued at $1,631,225,000 after acquiring an additional 869,175 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Pfizer by 0.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 50,540,119 shares of the biopharmaceutical company’s stock valued at $1,258,449,000 after acquiring an additional 410,082 shares in the last quarter. Finally, Amundi increased its stake in Pfizer by 13.4% in the fourth quarter. Amundi now owns 47,063,380 shares of the biopharmaceutical company’s stock valued at $1,171,879,000 after acquiring an additional 5,572,451 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.
Pfizer Company Profile
Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.
Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.
Read More
- Five stocks we like better than Pfizer
- The AI Chip Stock Making a Quiet Move Toward Dominance
- Why Walmart and Amazon Could Be the Market’s Most Complementary Mega-Caps
- Dodging Deutsche Telekom: T-Mobile’s Strategic Win
- GLP-1 Demand Is Creating a New Dividend Angle in These 4 Logistics Stocks
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
